<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-132924" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Casirivimab</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sherchan</surname>
            <given-names>Robin</given-names>
          </name>
          <aff>Baylor College of Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Cannady, Jr</surname>
            <given-names>Preston</given-names>
          </name>
          <aff>Chicago Medical School/ Rosalind Franklin University of Medicine and science</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Robin Sherchan declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preston Cannady, Jr declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>30</day>
          <month>1</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-132924.s1" sec-type="Indications">
        <title>Indications</title>
        <p content-type="pubmed-excerpt">As of January 24, 2022, according to the United States Food and Drug Association (FDA) fact sheet for casirivimab, "due to the high frequency of the Omicron variant, casirivimab&#x000a0;is not currently authorized for use in any U.S. region because of markedly reduced&#x000a0;activity against the omicron variant. This drug may not be administered for&#x000a0;treatment or post-exposure prevention of COVID-19 under the Emergency Use&#x000a0;Authorization until further notice by the Agency." This&#x000a0;topic is to be used only for a historical review of the development and use of this drug.&#x000a0;</p>
        <p>Casirivimab is a monoclonal antibody (mAb) against spike protein (S) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes coronavirus disease 2019 (COVID-19). It is&#x000a0;1 of the SARS-CoV-2 neutralizing antibodies proposed for use in the clinical management of COVID-19.<xref ref-type="bibr" rid="article-132924.r1">[1]</xref>&#x000a0;On 21st&#x000a0;November 2020, the combination of casirivimab and imdevimab was authorized for emergency use by the United States Food and Drug Administration (FDA). These are investigational drugs not approved for any specific indication. FDA allowed these drugs only to be&#x000a0;administered together. Casirivimab (REGN10933) and imdevimab (REGN10987) are also known as REGN-COV2 or Regeneron. The combination drug has been shown to decrease viral load<italic toggle="yes">&#x000a0;</italic>and decrease the risk of hospitalization and emergency visits. REGN-COV2, administered prophylactically or therapeutically, has prevented COVID-19-induced sequelae in non-human primates.<xref ref-type="bibr" rid="article-132924.r1">[1]</xref><xref ref-type="bibr" rid="article-132924.r2">[2]</xref>&#x000a0;</p>
        <p>FDA authorized the drug cocktail to be used only in nonhospitalized patients&#x000a0;who meet&#x000a0;all&#x000a0;3 following criteria:</p>
        <list list-type="order">
          <list-item>
            <p>Age &#x02265;12 years and weight &#x02265;40 kg&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Lab confirmed SARS-COV-2 infection</p>
          </list-item>
          <list-item>
            <p>Mild to moderate&#x000a0;symptoms, which were at higher risk of progression to severe disease or hospitalization.<xref ref-type="bibr" rid="article-132924.r3">[3]</xref><xref ref-type="bibr" rid="article-132924.r4">[4]</xref></p>
          </list-item>
        </list>
        <p>High-risk patients include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Age&#x000a0;&#x02265; 65 years</p>
          </list-item>
          <list-item>
            <p>Body mass index (BMI) &#x02265; 25 (If 12-17 years old - BMI&#x000a0;&#x02265; 85th percentile for their age and gender)</p>
          </list-item>
          <list-item>
            <p>Pregnancy</p>
          </list-item>
          <list-item>
            <p>Chronic kidney disease</p>
          </list-item>
          <list-item>
            <p>Diabetes</p>
          </list-item>
          <list-item>
            <p>Immunosuppressive disease, currently on immunosuppressive treatment</p>
          </list-item>
          <list-item>
            <p>Cardiovascular disease (including congenital heart disease) or hypertension</p>
          </list-item>
          <list-item>
            <p>Chronic obstructive pulmonary disease (COPD), asthma, or other chronic respiratory diseases</p>
          </list-item>
          <list-item>
            <p>Sickle cell disease</p>
          </list-item>
          <list-item>
            <p>Neurodevelopmental disorders (eg, cerebral palsy)</p>
          </list-item>
          <list-item>
            <p>Medical device dependency (eg, tracheostomy, gastrostomy, positive pressure ventilation [not related to COVID-19])</p>
          </list-item>
        </list>
        <p>On June 3, 2021, the FDA updated the emergency use authorization, lowering the dosage of casirivimab and imdevimab to 600 mg each, an option for subcutaneous (SQ) administration. Another update on November 17, 2021, authorizing casirivimab and imdevimab (subcutaneously) for emergency use as post-exposure prophylaxis for COVID-19 in adults. It was recommended for patients who are vaccinated but not expected to mount adequate immune response or&#x000a0;who are not fully vaccinated.<xref ref-type="bibr" rid="article-132924.r5">[5]</xref>&#x000a0;It is recommended that the medication be started as soon as possible after a positive SARS-CoV-2 test and within 10 days of symptom onset. This is because active viral replication occurs between days 1&#x000a0;and 10 of symptoms, and these medications are&#x000a0;unlikely to be beneficial later. When administered to hospitalized COVID-19 patients requiring high-flow oxygen or ventilator support, monoclonal antibodies are likely associated with worse clinical outcomes. Casirivimab and imdevimab combination are not authorized for patients hospitalized or require oxygen therapy for COVID-19. Viral load reductions with intravenous (IV) and SQ appear similar, but data on SQ administration is limited.<xref ref-type="bibr" rid="article-132924.r5">[5]</xref><xref ref-type="bibr" rid="article-132924.r6">[6]</xref></p>
        <p>This being said it is still reasonable to consider this drug combination in patients who test positive for SAR-COV-2 infection but are hospitalized due to some other indication. Patients or parents/caregivers have the option to accept or refuse this combination drug treatment. If treated with the drug cocktail, patients should continue to self-isolate and use infection control measures such as wearing masks, social distancing, disinfecting surfaces, and maintaining hand hygiene. Monoclonal antibodies&#x000a0;provide&#x000a0;rapid protection against infection, and protection can last for weeks to months. For patients receiving passive antibody therapy (eg, mAbs), the recommendation is to defer COVID-19 vaccination&#x000a0;for at least 90 days to avoid potential interference with the immune response.<xref ref-type="bibr" rid="article-132924.r7">[7]</xref>&#x000a0;Please review the latest Centers for Disease Control and Prevention (CDC) and FDA recommendations on these medications. With new virus variants emerging, the indications and conditions for use are likely to change.</p>
      </sec>
      <sec id="article-132924.s2" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Casirivimab is a recombinant neutralizing human immunoglobulin G1 (IgG1) monoclonal antibody to the spike protein of SARS-CoV-2. It binds to the S1&#x000a0;subunit of the spike protein receptor-binding domain (RBD), blocking the attachment of&#x000a0;SARS-CoV-2&#x000a0;to the human ACE2 receptor. This prevents viral binding to the host cell, thereby preventing entry and replication of the virus, thus decreasing the viral load.&#x000a0;Imdevimab binds to a non-overlapping portion of the spike protein RBD, similar to casirivimab, and the combination is theorized to limit the development of viral mutations. The cocktail of the&#x000a0;2 drugs was also found to have retained activity against the Alpha (B.1.1.7; UK), Beta (B.1.351; South Africa), Gamma (P.1; Brazil), Delta (B.1.617.2; India), Epsilon (B.1.427/429; California), Iota (B.1.526; New York), and Kappa (B.1.617.1; India) variants of SARS-CoV-2.&#x000a0;The combination drug has no activity to&#x000a0;the Omicron variant.<xref ref-type="bibr" rid="article-132924.r5">[5]</xref><xref ref-type="bibr" rid="article-132924.r7">[7]</xref><xref ref-type="bibr" rid="article-132924.r8">[8]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-132924.s3" sec-type="Administration">
        <title>Administration</title>
        <p>Carsirivimab is not authorized to be used alone. The authorized dosage is a combination of casirivimab 600 mg + imdevimab 600 mg (was previously casirivimab&#x000a0;1200 mg + imdevimab&#x000a0;1200 mg) administered as a single IV infusion. There is an option for&#x000a0;SQ&#x000a0;administration as an alternative route if awaiting IV infusion would delay treatment, though IV infusion is still preferred. The pediatric dose of the drug combination for age&#x000a0;&#x02265; 12 years and weight&#x000a0;&#x02265; 40 kg is the same as the adult dose. For post-exposure prophylaxis, casirivimab 600 mg + imdevimab 600 mg is administered together as a single IV infusion (or SQ) as soon as possible following exposure to SARS-CoV-2.&#x000a0;In case of ongoing exposure to&#x000a0;SARS-CoV-2 for &#x0003e;4 weeks who are determined appropriate and vaccinated patients not expected to&#x000a0;mount an adequate immune response, a subsequent&#x000a0;dose of casirivimab 300 mg + imdevimab 300 mg once every 4 weeks can be repeated for the duration of ongoing exposure.</p>
        <p>Casirivimab and imdevimab each come in individual single-use vials or co-formulated single vials. If individual vials are used, the drugs must be diluted and mixed by qualified healthcare professionals using an aseptic technique before infusion.<xref ref-type="bibr" rid="article-132924.r7">[7]</xref>&#x000a0;Once diluted, the solution should be used immediately. Storage after dilution can be done in a refrigerator&#x000a0;or left at room temperature for up to 4 hours, including infusion time. While the infusion is ongoing&#x000a0;and up to 1 hour after completion, patients should be monitored for hypersensitivity reactions. The infusion should only occur in settings where healthcare providers have immediate access to medication to treat infusion-related reactions, such as anaphylaxis. In cases of renal impairment, no dose adjustment is needed. Casirivimab and imdevimab are not eliminated intact in the urine, so renal impairment should not affect the exposure to the drugs. The effect on the pharmacokinetics of casirivimab in the presence of hepatic impairment is still unknown.<xref ref-type="bibr" rid="article-132924.r5">[5]</xref></p>
      </sec>
      <sec id="article-132924.s4" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Limited data is available for adverse effects of casirivimab, but other adverse effects may come to light in the future. Adverse effects reported include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Hypersensitivity including anaphylaxis (8,000 mg dose)</p>
          </list-item>
          <list-item>
            <p>Infusion-related reactions included pyrexia, chills, abdominal pain, flushing, urticaria, and pruritus (8,000 mg dose)</p>
          </list-item>
          <list-item>
            <p>Nausea and Vomiting (2,400 mg dose)</p>
          </list-item>
        </list>
        <p>Due to the possibility of hypersensitivity, including anaphylaxis and infusion-related reactions, observation in the infusion center is advised for at least&#x000a0;1 hour post-transfusion. Slow or stop the infusion and consider administering relevant medications&#x000a0;or supportive care if&#x000a0;there is a concern for an infusion-related reaction.<xref ref-type="bibr" rid="article-132924.r5">[5]</xref><xref ref-type="bibr" rid="article-132924.r9">[9]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-132924.s5" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>There&#x000a0;are no absolute contraindications for&#x000a0;Casirivimab.&#x000a0;</p>
        <p>Casirivimab and imdevimab combination is not authorized for use in patients with any of the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Age &#x0003c; 12 years and weight &#x0003c; 40 kg</p>
          </list-item>
          <list-item>
            <p>Hospitalized&#x000a0;due to COVID-19</p>
          </list-item>
          <list-item>
            <p>Requiring oxygen support</p>
          </list-item>
          <list-item>
            <p>Patients with underlying non-COVID-19 related comorbidities already on oxygen therapy who have an increase in baseline oxygen requirement&#x000a0;from COVID-19<xref ref-type="bibr" rid="article-132924.r5">[5]</xref>&#x000a0;</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-132924.s6" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Observation is required for infusion-related and hypersensitivity reactions, including anaphylaxis during and at least&#x000a0;1 hour after infusion completion.<xref ref-type="bibr" rid="article-132924.r5">[5]</xref>&#x000a0;On arrival at the infusion center, clinical stability must be assessed as the patient's symptoms may have worsened since the initial plan for infusion was made. In cases where the patient's symptoms have worsened, the decision should be made if patients need to be evaluated further for the possible need for hospitalization. Post-infusion, patients must be monitored for at least 7 days for any serious adverse effects.&#x000a0;Casirivimab and imdevimab are not renally excreted or metabolized by cytochrome P450 enzymes. Therefore, interactions are unlikely when given together with renally excreted medications, inducers, substrates, or inhibitors of cytochrome P450 enzymes.<xref ref-type="bibr" rid="article-132924.r5">[5]</xref><xref ref-type="bibr" rid="article-132924.r7">[7]</xref></p>
      </sec>
      <sec id="article-132924.s7" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>The recommended dose of casirivimab is 600 mg, along with imdevimab 600 mg. In studies, doses up to 8 g (4000 mg of each drug) have been administered without dose-limiting toxicity.&#x000a0;In overdose situations, general supportive measures, including vital signs and clinical status monitoring, are recommended. There is no specific antidote for toxicity due to overdose.</p>
        <p>&#x000a0;<bold>Pregnancy and Lactation</bold>&#x000a0;<xref ref-type="bibr" rid="article-132924.r10">[10]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Casirivimab is a humanized monoclonal antibody (IgG1). Placental transfer of IgG depends on different factors, such as maternal serum IgG level and IgG subclass.<xref ref-type="bibr" rid="article-132924.r11">[11]</xref>&#x000a0;Further data are&#x000a0;needed to classify risk or benefit to the fetus.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Maternal IgG is present in breast milk. Casirivimab is a large protein molecule with a molecular weight of over 145,000 Da, so the amount in milk is probably low, and it is also likely partially destroyed in the infant's gastrointestinal tract. Therefore, absorption by the infant is likely low. No information is available&#x000a0;related to using casirivimab during breastfeeding. According to the emergency use authorization, the decision to breastfeed during therapy should depend on the benefit of treatment of the mother and the benefits and risk of exposure to the infant.</p>
          </list-item>
          <list-item>
            <p>No dose adjustment is recommended for pregnant or lactating patients per emergency use authorization by FDA (FDA 2021).</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-132924.s8" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Casirivimab is a monoclonal antibody authorized for emergency use by the FDA due to the ongoing COVID-19 pandemic. Initial results show a decrease in&#x000a0;viral load and clinical benefit if the drug is initiated early in high-risk patients with mild to moderate disease.<xref ref-type="bibr" rid="article-132924.r9">[9]</xref>&#x000a0;More adverse effects related to the drug might be reported in the future. Therefore, when the drug is being used, the prescribing physician, nurses, and pharmacists need close safety monitoring. Providers should be vigilant of any potential drug-related adverse effects. Educating the patient regarding the drug is crucial.&#x000a0;The drug combination is administered via IV infusion or SQ, and there is the possibility of infusion and injection-related side effects, including pyrexia, chills, abdominal pain, flushing, urticaria, and pruritus, along with hypersensitivity and anaphylaxis. Observation in the infusion center after transfusion for at least 60 minutes is recommended.&#x000a0;The&#x000a0;interprofessional team of healthcare professionals&#x000a0;must have the necessary medications and equipment in the room to ensure safe outcomes. Proper and prompt intervention can be life-saving in cases such as anaphylaxis.<xref ref-type="bibr" rid="article-132924.r7">[7]</xref>&#x000a0;Pharmacists can help clinicians and nurses ensure proper dosing, monitor drug interactions, and educate patients and staff on potential side effects. Proper collaboration between interprofessional healthcare team members helps achieve optimal patient outcomes while minimizing patient risks.</p>
      </sec>
      <sec id="article-132924.s9">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=132924&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=132924">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/132924/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=132924">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-132924.s10">
        <title>References</title>
        <ref id="article-132924.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hurt</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Wheatley</surname>
                <given-names>AK</given-names>
              </name>
            </person-group>
            <article-title>Neutralizing Antibody Therapeutics for COVID-19.</article-title>
            <source>Viruses</source>
            <year>2021</year>
            <month>Apr</month>
            <day>07</day>
            <volume>13</volume>
            <issue>4</issue>
            <pub-id pub-id-type="pmid">33916927</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132924.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baum</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ajithdoss</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Copin</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lanza</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Negron</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ni</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Mohammadi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Musser</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Atwal</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Oyejide</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Goez-Gazi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Dutton</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Clemmons</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Staples</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Bartley</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Klaffke</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Alfson</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Gazi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gonzalez</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Dick</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Carrion</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pessaint</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Porto</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cook</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ali</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Greenhouse</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Andersen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Lewis</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Stahl</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Murphy</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Yancopoulos</surname>
                <given-names>GD</given-names>
              </name>
              <name>
                <surname>Kyratsous</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <article-title>REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters.</article-title>
            <source>Science</source>
            <year>2020</year>
            <month>Nov</month>
            <day>27</day>
            <volume>370</volume>
            <issue>6520</issue>
            <fpage>1110</fpage>
            <page-range>1110-1115</page-range>
            <pub-id pub-id-type="pmid">33037066</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132924.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kaplon</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Reichert</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Antibodies to watch in 2021.</article-title>
            <source>MAbs</source>
            <year>2021</year>
            <season>Jan-Dec</season>
            <volume>13</volume>
            <issue>1</issue>
            <fpage>1860476</fpage>
            <pub-id pub-id-type="pmid">33459118</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132924.r4">
          <label>4</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Cascella</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rajnik</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Aleem</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dulebohn</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Di Napoli</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <chapter-title>Features, Evaluation, and Treatment of Coronavirus (COVID-19)</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>18</day>
            <pub-id pub-id-type="pmid">32150360</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132924.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <article-title>An EUA for casirivimab and imdevimab for COVID-19.</article-title>
            <source>Med Lett Drugs Ther</source>
            <year>2020</year>
            <month>Dec</month>
            <day>28</day>
            <volume>62</volume>
            <issue>1614</issue>
            <fpage>201</fpage>
            <page-range>201-202</page-range>
            <pub-id pub-id-type="pmid">33451174</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132924.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Singanayagam</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Charlett</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lopez Bernal</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Saliba</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ellis</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ladhani</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zambon</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gopal</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Duration of infectiousness and correlation with RT-PCR cycle threshold values in cases of COVID-19, England, January to May 2020.</article-title>
            <source>Euro Surveill</source>
            <year>2020</year>
            <month>Aug</month>
            <volume>25</volume>
            <issue>32</issue>
            <pub-id pub-id-type="pmid">32794447</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132924.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pallotta</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gordon</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Monoclonal antibodies for treating COVID-19.</article-title>
            <source>Cleve Clin J Med</source>
            <year>2021</year>
            <month>Feb</month>
            <day>17</day>
            <pub-id pub-id-type="pmid">33597176</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132924.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baum</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fulton</surname>
                <given-names>BO</given-names>
              </name>
              <name>
                <surname>Wloga</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Copin</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pascal</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Russo</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Giordano</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lanza</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Negron</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ni</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Atwal</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Murphy</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Stahl</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Yancopoulos</surname>
                <given-names>GD</given-names>
              </name>
              <name>
                <surname>Kyratsous</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <article-title>Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies.</article-title>
            <source>Science</source>
            <year>2020</year>
            <month>Aug</month>
            <day>21</day>
            <volume>369</volume>
            <issue>6506</issue>
            <fpage>1014</fpage>
            <page-range>1014-1018</page-range>
            <pub-id pub-id-type="pmid">32540904</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132924.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weinreich</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Sivapalasingam</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Norton</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ali</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gao</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Bhore</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Musser</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Soo</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Rofail</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Im</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Perry</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pan</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hosain</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mahmood</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Turner</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Hooper</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Hamilton</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Baum</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kyratsous</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Cook</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kampman</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Kohli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sachdeva</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Graber</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Kowal</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>DiCioccio</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Stahl</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Lipsich</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Braunstein</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Herman</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Yancopoulos</surname>
                <given-names>GD</given-names>
              </name>
              <collab>Trial Investigators</collab>
            </person-group>
            <article-title>REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19.</article-title>
            <source>N Engl J Med</source>
            <year>2021</year>
            <month>Jan</month>
            <day>21</day>
            <volume>384</volume>
            <issue>3</issue>
            <fpage>238</fpage>
            <page-range>238-251</page-range>
            <pub-id pub-id-type="pmid">33332778</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132924.r10">
          <label>10</label>
          <element-citation publication-type="book">
            <chapter-title>Casirivimab</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2023</year>
            <month>11</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">33226742</pub-id>
          </element-citation>
        </ref>
        <ref id="article-132924.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Palmeira</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Quinello</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Silveira-Lessa</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Zago</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Carneiro-Sampaio</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>IgG placental transfer in healthy and pathological pregnancies.</article-title>
            <source>Clin Dev Immunol</source>
            <year>2012</year>
            <volume>2012</volume>
            <fpage>985646</fpage>
            <pub-id pub-id-type="pmid">22235228</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
